MetaCap

China Pharma (CPHI) vs IGC Pharma (IGC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

IGC Pharma (IGC) has outperformed China Pharma (CPHI) over the past year, losing 47.5% versus a loss of 72.6%. Over five years, IGC leads with a -87.6% price change compared with -99.8% for CPHI. IGC Pharma is the larger company by market cap ($19.6 million vs $18.9 million), about 1.0 times the size.

China Pharma converts more of its revenue into profit, with a net margin of -76.9% versus -560.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CPHI-72.60%IGC-47.50%
+430%+167%-97%
Nov 21, 20251 yearNov 20, 2026
CPHI-99.85%IGC-88.25%
+5%-50%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CPHI versus IGC key metrics
MetricCPHIIGC
Share price$0.4384$0.168
Market cap$18.86M$19.60M
1-day change-13.00%-8.70%
YTD return-63.77%-40.00%
1-year return-72.60%-47.50%
5-year return-99.84%-87.65%
EPS (TTM)$-0.42$-0.07
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$4.14M$1.27M
Revenue growth (YoY)-8.49%-5.50%
Net income (latest FY)$-3.19M$-7.12M
Gross margin-3.18%48.70%
Operating margin-78.16%-585.84%
Net margin-76.91%-560.35%
52-week high$19.19$0.36
52-week low$0.38$0.08
Distance from 52-week high-97.72%-53.33%
Analyst consensus—none
Avg. price target upside—+3471.43%
Average volume1.60M615.25K
Shares outstanding43.02M116.69M
Employees21570
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IGC has outperformed CPHI by 25.1 percentage points over the past year.
  • China Pharma is more profitable, keeping -76.9 cents of every revenue dollar as net income versus -560.3 cents for IGC Pharma.

About China Pharma

CPHI stock →

China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China.

Health Care · Biotechnology: Pharmaceutical Preparations · 215 employees

About IGC Pharma

IGC stock →

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's.

Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees

CPHI vs IGC FAQ

Which is bigger, China Pharma or IGC Pharma?

IGC Pharma (IGC) is larger, with a market capitalization of $19.60M compared with $18.86M for China Pharma (CPHI).

Which stock has performed better over the past year, CPHI or IGC?

IGC returned -47.50% over the past 12 months, compared with -72.60% for CPHI (price return, excluding dividends). Past performance does not predict future results.

Are China Pharma and IGC Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons